</P> <P> When Neaton faxed him the ``unblinded'' data, the signal was clear: Within the small population of people suffering from cardiovascular disease, the number from the Vioxx group after 18 months of study was twice as high as the placebo group -- 15 heart attacks or strokes per 1,000 patients per year, versus 7. </P> <P> ``When I saw the last set of data, I knew we had a tough decision to make,'' said James Neaton, a University of Minnesota biostatistician, who had monitored a dozen other studies but seldom had seen such troubling data . </P> <P>
